芪胶升白胶囊治疗白细胞减少症的Meta分析与临床应用研究
首发时间:2018-07-27
摘要:目的:评价芪胶升白胶囊治疗白细胞减少症疗效与安全性。方法:检索PubMed、Cochrane Library、EMBASE、CNKI、万方、维普和中国生物医学文献数据库(2008~2018),选取芪胶升白胶囊治疗白细胞减少症的随机对照试验文献,对纳入研究文献的方法学以及文献质量进行评价,随后采用STATA 12.0软件进行Meta分析。结果:共纳入36项临床研究文献。Meta分析结果显示:芪胶升白胶囊与对照治疗比较,总有效率(RR=1.326,95%CI:1.247~1.409);显效率(RR=1.949,95%CI:1.694~2.244);白细胞减少率(RR=0.661, 95%CI:0.559~0.782);Ⅲ 白细胞减少率(RR=0.275,95%CI:0.173~0.436);白细胞水平:WMD=2.923,95%CI:2.272~3.574。结论:芪胶升白胶囊能有效防治疗因药物,特别是化疗药物、射线或不明原因导致的白细胞减少症,且具有良好的临床用药安全性,值得临床推广应用。
关键词: 中医内科学 芪胶升白胶囊 白细胞减少症 随机对照试验 Meta分析
For information in English, please click here
Meta-analysis and clinical application on Qijiao Shengbai Capsule for leukopenia
Abstract:Objective: To evaluate the efficacy and safety of Qijiao Shengbai Capsule in the treatment of leukopenia. Methods: Randomized controlled trails (RCTs) of Qijiao Shengbai Capsule for leukopenia were searched from PubMed, Cochrane Library, EMBASE, CNKI, Wan Fang, VIP and the Chinese biomedical literature database were searched (2008~2018). The methodological quality of included studies was evaluated, and data analyses were performed with STATA 12.0. Results: A total of 36 RCTs were included. Meta-analysis showed that Qijiao Shengbai Capsule compared with control group resulted in total effective rate(RR=1.326, 95%CI:1.247~1.409, P=0.000<0.05), in apparent rate(RR=1.949, 95%CI:1.694~2.244, P=0.000<0.05), in leucocytopenia rate(RR=0.661, 95%CI:0.559~0.782, P=0.000<0.05), in Ⅲ leucocytopenia rate(RR=0.275, 95%CI:0.173~0.436, P=0.000<0.05), in WBC level (WMD=2.923, 95%CI:2.272~3.574, P=0.000<0.05). Conclusion: Qijiao Shengbai Capsule can be effectively used to prevent the treatment of drugs, especially chemotherapy drugs, radiation or unexplained leukopenia, with good clinical safety. Qijiao Shengbai Capsule is worthy of clinical application.
Keywords: Internal medicine of TCM Qijiao Shengbai Capsule leukopenia randomized controlled trial Meta-analysis
引用
No.****
动态公开评议
共计0人参与
勘误表
芪胶升白胶囊治疗白细胞减少症的Meta分析与临床应用研究
评论
全部评论0/1000